Patents Assigned to Genzyme Corporation
  • Amide dendrimer compositions
    Patent number: 8900560
    Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: December 2, 2014
    Assignee: Genzyme Corporation
    Inventors: Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
  • INHIBITORS OF T-CELL ACTIVATION
    Publication number: 20140348832
    Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 27, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
  • ANTI-HUMAN CD52 IMMUNOGLOBULINS
    Publication number: 20140341910
    Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
    Type: Application
    Filed: November 26, 2013
    Publication date: November 20, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
  • Amido-amine polymer compositions
    Patent number: 8889738
    Abstract: Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: November 18, 2014
    Assignee: Genzyme Corporation
    Inventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval
  • DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
    Publication number: 20140335070
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: January 16, 2014
    Publication date: November 13, 2014
    Applicants: Genzyme Corporation, Icahn School of Medicine at Mount Sinai
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease
    Publication number: 20140336174
    Abstract: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 13, 2014
    Applicant: Genzyme Corporation
    Inventors: Oxana Ibraghimov-Beskrovnaya, Thomas A. Natoli
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140322319
    Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m particles and used for treating patients, for example, patients with hyperphosphatemia.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 30, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Stephen Randall Holmes-Farley, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
  • Affinity-Based Analytical Purification Of Biotherapeutics For Bioprocess Monitoring
    Publication number: 20140322699
    Abstract: The invention as disclosed herein provides a method for purifying a non-antibody protein from solution, comprising a chromatography step wherein the solution is passed over an affinity construct containing an affinity ligand-coupled solid support, wherein the affinity construct is associated with a bioprocess unit operation, and isolating the non-antibody protein from solution.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Applicant: Genzyme Corporation
    Inventors: Veena Warikoo, Kevin Brower
  • FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF
    Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Anti-CXCR3 antibodies and methods of use thereof
    Patent number: 8865870
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: October 21, 2014
    Assignee: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
    Patent number: 8852607
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 7, 2014
    Assignee: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
    Publication number: 20140294867
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 2, 2014
    Applicant: Genzyme Corporation
    Inventors: Clark PAN, Qun ZHOU, James STEFANO, Pradeep DHAL, Bo CHEN, Diego GIANOLIO, Robert MILLER, Huawei QIU
  • NON-LITHOTRIPSIC KIDNEY-STONE THERAPY
    Publication number: 20140288569
    Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
    Type: Application
    Filed: April 22, 2014
    Publication date: September 25, 2014
    Applicants: Genzyme Corporation, The General Hospital Corporation
    Inventors: W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
  • Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and applications thereof
    Patent number: 8841427
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 23, 2014
    Assignee: Genzyme Corporation
    Inventor: Yunxiang Zhu
  • HIGH DENSITY CELL BANKING METHODS
    Publication number: 20140273206
    Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Xiaoxia JIN, Haodi DONG, Claudia BUSER
  • FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
    Publication number: 20140271676
    Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Clark PAN, Huawei QIU
  • METHODS OF MEASURING CELL VIABILITY IN TISSUE ENGINEERED PRODUCTS
    Publication number: 20140273050
    Abstract: This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventor: Yongzhong Wang
  • AMINE FUNCTIONAL POLYAMIDES
    Publication number: 20140275469
    Abstract: Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Pradeep DHAL, Kanwen Yang, Robert J. Miller, S. Randall Holmes-Farley
  • THERMO-SENSITIVE BONE GROWTH COMPOSITIONS
    Publication number: 20140271471
    Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
  • Oligosaccharide-protein conjugates
    Patent number: 8835614
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: September 16, 2014
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young